<DOC>
	<DOC>NCT00992654</DOC>
	<brief_summary>The new protocol will allow the patients enrolled on A4001050 to have continuous access of Maraviroc and the treatment will not be interrupted until the drug is commercially available in India.</brief_summary>
	<brief_title>A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>Subjects who complete the A4001050 study and are continuing to derive benefit from Maraviroc. Subjects who are willing and able to comply with scheduled visits, treatment plan and other study procedures. Subjects who discontinued in A4001050 study. Unable to provide consent.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Open Label Access Program</keyword>
	<keyword>Treatment experienced</keyword>
</DOC>